- Remdesivir is an experimental antiviral drug made by the company Gilead. Designed to act against the RNA driven RNA polymerase enzyme in RNA viruses, it was initially tested on Ebola.
- Since coronaviruses are also RNA viruses, Remdesivir is expected to work on them, too.
- Published in The Lancet: Clinical trial of remdesivir in adults with severe COVID-19
- Randomized, double-blinded
- 237 patients
- Placebo controlled
- Multi-center
- 10 hospitals in China
- Bottom line
- Any improvement was not statistically significant
- Randomized, double-blinded
Remdesivir Hopes
